Amicus Therapeutics Stock News

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -12.50% and 0.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Amicus Therapeutics (NASDAQ:FOLD) unveils its next round of earnings this Monday, March 01. Get prepared with Benzinga's ultimate preview for Amicus Therapeutics's Q4 earnings.

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amicus Therapeutics said Thursday its rare-disease treatment failed to outperform a standard drug on one key measure in a Phase 3 test. In response, FOLD stock plunged on Friday.

Shares of Amicus Therapeutics Inc. were down 23.1% in premarket trading on Friday, the day after the company said an experimental rare disease drug failed to perform better than the standard of care i

CNBC Meg Tirrell talks with Amicus Therapeutics CEO John Crowley about trial results for a drug to treat Pompe disease. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Kare

CNBC's senior health and science reporter Meg Tirrell reports Amicus showed results in its phase 3 trial to address Pompe disease. The drug showed it can help people walk and significantly slowed the

Rolling BLA submission for AT-GAA planned for completion in Q2 and other global regulatory submissions for approval expected throughout 2021

Amicus Optimized Transgene Show Greater Substrate Reduction than Wild Type Construct Across All Tissues and Doses

Investors need to pay close attention to Amicus Therapeutics (FOLD) stock based on the movements in the options market lately.

CRANBURY, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines

CRANBURY, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the 39th Annual J.P. Mo

A group of tech companies including Microsoft today filed an amicus brief in a case brought by WhatsApp against NSO Group.

The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.

Biopharma stocks are risky investment bets that sway wildly in reaction to catalytic events. Binary events scheduled for Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Sarepta Therapeutics Inc (NASDAQ: